Citurgia Biochemicals Limited attributed the delayed disclosure of its Registrar of Companies (ROC) approval for an AGM extension to internal communication lapses and confirmation delays. The company missed the 24-hour timeline mandated by SEBI regulations after receiving approval on September 18, 2026, to hold its meeting by October 31, 2026.

The management stated it erroneously believed the disclosure would occur automatically upon receipt of the ROC permission. The company has since strengthened its internal reporting mechanisms to ensure future compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Approval Details

The ROC, Mumbai, granted a one-month extension under Section 96(1) of the Companies Act, 2013. This allows Citurgia to convene its 51st Annual General Meeting for the financial year ended March 31, 2026, by October 31, 2026. The original statutory deadline was September 30, 2026.

Disclosure Timeline and Explanation

Citurgia initially sought a three-month extension until December 31, 2025, via a board resolution dated August 31, 2026. The ROC approved only a one-month extension in its letter dated September 18, 2026. The material event occurred on August 31, 2026, but the company failed to inform BSE Limited within the prescribed period due to inadvertent error.

Kashi Nath, Whole Time Director, signed the explanation letter submitted to BSE on September 25, 2026. He confirmed that the delay was not intentional and requested the exchange to condone the lapse. The company reiterated that the specific date of the AGM will be intimated within the extended timeline.

Compliance Advisory

In its order, the ROC advised Citurgia to ensure careful compliance with the provisions of the Companies Act, 2013, in future filings. The regulatory body noted that while the extension was granted, strict adherence to statutory timelines is critical for corporate governance standards.

Citurgia Biochemicals Limited reported a standalone loss of ₹8.20 lakh for the quarter ended June 30, 2026 (Q1FY27). The loss narrowed significantly from ₹8.39 lakh in the corresponding quarter of FY26, driven by a reduction in operational expenses despite zero revenue generation.

The Mumbai-based biochemical firm disclosed zero total income from operations for Q1FY27, consistent with its performance in the preceding quarter and the full year ended March 31, 2026. The Board of Directors approved the unaudited financial results on August 14, 2026.

Financial Performance

The company’s expense structure contracted sharply in the current quarter compared to the previous period. Total expenses fell to ₹8.20 lakh from ₹25.82 lakh in Q4FY26. This decline was primarily attributable to lower other expenses, which dropped to ₹0.05 lakh from ₹14.15 lakh in the preceding quarter.

Employee benefit expenses remained stable at ₹3.00 lakh, while depreciation and amortisation costs decreased slightly to ₹5.15 lakh from ₹5.73 lakh. For the full fiscal year 2026, the company incurred a total loss of ₹74.25 lakh against nil revenue.

What the Numbers Show

The absence of any operating income or other income indicates that the company is not currently generating cash flows from business activities. The profit before tax matches the total expenses exactly, confirming that the entire loss is driven by fixed overheads such as employee benefits and depreciation rather than variable costs linked to production or sales volume.